Podcast Episodes
Back to Search
Raymond James Biotech Innovation Symposium: Akebia's CEO John Butler shares an update on the launch of Vafseo and discusses two of the company's pipeline programs
He describes physician, patient, and payor feedback from this closely watched launch. Plus, praliciguat, and why Akebia bought a targeted complement …
5 months ago
Raymond James Biotech Innovation Symposium: Wave Life Sciences CEO Paul Bolno discusses the recent INHBE data and previews alpha-1 antitrypsin deficiency data being presented next month
He discusses the INHBE data and the market reaction to it, which he believes is due to misconceptions about the patient population, and the next step…
5 months ago
Raymond James Biotech Innovation Symposium: Tectonic Therapeutic develops biologics against GPCR targets - and is making headway on an unmet need for pulmonary hypertension in heart failure patients
CEO Alice Reicin walks us through recent data and guides for what is next in this patient population. Plus, an upcoming healthily volunteer readout f…
5 months ago
Raymond James Biotech Innovation Symposium: Eupraxia has a novel extended release platform for - with data already out and more on the way later this year, Eosinophilic Esophagitis has been a good PoC
CEO James Helliwell describes Eupraxia's platform and how it differs from other extended release technologies. Plus, Eosinophilic Esophagitis, and ho…
5 months ago
Raymond James Biotech Innovation Symposium: Septerna is developing oral small molecules that target GPCRs, it now has two programs in the clinic
Co-Founder and CEO Jeffrey Finer describes how Septerna is able to screen for GPCR targets in ways that have not previously been possible. Plus, an o…
5 months ago
Raymond James Biotech Innovation Symposium: Raymond James analyst Chris Raymond shares his take on biotech and companies he covers
He discusses Tyra, Sionna, Alumis, Nuvalent, and Monopar.
5 months ago
Harbinger Health is announcing its emphasis on a new category of cancer screening tests today, RESOLVE, that are meant to be used upon the suspicion of cancer symptoms to speed diagnosis and treatment
CEO Ajit Singh describes the idea behind the new products, and highlights that $100M has been raised to fund the development of them.
5 months ago
Spyre Therapeutics announced today that SPY001, an extended half-life α4β7, showed a 40% clinical remission rate at 12 weeks in moderate-to-severe UC
CEO Cameron Turtle walks us through the data, shares his opinion on its translatability to part B of the current study, and tells us what else is ahe…
5 months ago
Alloy Therapeutics announced a deal with Biogen today to help them discover antisense therapeutics using Alloy's ASO platform. Alloy Founder & CEO Errik Anderson fills us in at the company's R&D Day.
He discusses the Biogen deal, and how it is a sign of increased activity Alloy sees in their genetic medicines business. Plus, monoclonals vs multisp…
5 months, 1 week ago
The new CEO of Stoke Therapeutics, Ian Smith, discusses Stoke Therapeutics' Dravet syndrome therapy, which caught much attention after publishing phase 1/2 data in NEJM last month
He describes how Stoke aims to up-regulate healthy genes in cases where diseases are caused by autosomal dominant haploinsufficiencies, like Dravet. …
5 months, 1 week ago